Trial reportClinical cardiology2018
C-reactive protein during and after myocardial infarction in relation to cardiac injury and left ventricular function at follow-up.
Trial report in Clinical cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 54 citations in OpenAlex.
- Montelukast impressively mitigates biomarkers of inflammation in non-ST-segment elevation myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial.Inflammopharmacology · 2021Trial
- C-reactive protein during and after myocardial infarction in relation to cardiac injury and left ventricular function at follow-up.Clinical cardiology · 2018Trial
- Association of systemic inflammation with major adverse cardiovascular events in patients with acute myocardial infarction.American journal of preventive cardiology · 2026Article
- Observational
- Admission C-Reactive Protein and Mortality After STEMI: A Retrospective Cohort Study Identifying Subgroup-Specific Risk Thresholds.Journal of clinical medicine · 2026Article
- The CALLY index as a novel predictor of left ventricular aneurysm in patients with ST-segment elevation myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
- Machine Learning-Based Prediction of Early Left Ventricular Function After STEMI.Journal of clinical medicine · 2025Article
- Article
- Battle of the Biomarkers of Systemic Inflammation.Biology · 2025Review
- Combined complement and coagulation activation in ST-elevation myocardial infarction: associations with myocardial injury and dysfunction.Frontiers in immunology · 2025Article
- Effects of intensive rosuvastatin on ventricular remodeling and cardiac function in elderly patients with STEMI undergoing PCI.Frontiers in cardiovascular medicine · 2025Article
- Interplay between Pro-inflammatory Mediators and Oxidative Stressinvolved Recurrent Chronic Heart Failure in Elderly Patients with Coronary Stents.Current medicinal chemistry · 2025Article
- Comprehensive Quality Analysis of Conventional and Novel Biomarkers in Diagnosing and Predicting Prognosis of Coronary Artery Disease, Acute Coronary Syndrome, and Heart Failure, a Comprehensive Literature Review.Journal of cardiovascular translational research · 2024Review
- Association between C-reactive protein to albumin ratio and subclinical myocardial injury in the general population free from cardiovascular disease.Journal of cardiothoracic surgery · 2024Article
- IL10 promoter variants are associated with gene expression but they are not markers of susceptibility to acute coronary syndrome.Scientific reports · 2024Article
- Adipose Dysfunction Indices as a Key to Cardiometabolic Risk Assessment-A Population-Based Study of Post-Myocardial Infarction Patients.Metabolites · 2024Article
- The CRP troponin test (CTT) stratifies mortality risk in patients with non-ST elevation myocardial infarction (NSTEMI).Clinical cardiology · 2024Article
- The COVID-19 Pandemic and Coronary Heart Disease: the Next Surge.Current atherosclerosis reports · 2023Review
- The Impact of Systemic Inflammation Response Index on the Prognosis of Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.Reviews in cardiovascular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAcute myocardial infarction (MI) invokes a large inflammatory response, which contributes to myocardial repair. HYPOTHESIS: We investigated whether C-reactive protein (CRP) measured during MI vs at 1 month follow-up improves the prediction of left ventricular (LV) function.
methodsWe prospectively enrolled 131 consecutive patients with acute MI and without non-cardiovascular causes of inflammation. We correlated admission and peak levels of CRP during hospitalization and high-sensitivity (hs) CRP at 1 month follow-up with markers of cardiac injury. Clinical follow-up and echocardiography for LV function were performed at a mean of 17 months.
resultsMedian CRP levels were 1.89 mg/L on admission with MI, peaked to 12.10 mg/L during hospitalization and dropped to 1.24 mg/L at 1 month. Although admission CRP levels only weakly correlated with ejection fraction in the acute phase of MI (coefficient -0.164, P = 0.094), peak CRP was significantly related to ejection fraction (coefficient -0.4, P < 0.001), hsTroponin T (0.389, P < 0.001), and white blood cell count (0.389, P < 0.001). hsCRP at 1 month was not related to the extent of acute cardiac injury. These findings were replicated in an independent cohort of 57 patients. Peak CRP predicted LV dysfunction at follow-up (OR 11.0, 3.1-39.5 per log CRP, P < 0.001), persisting after adjustment for infarct size (OR 5.1, 1.1-23.6, P = 0.037), while hsCRP at 1 month was unrelated to LV function at follow-up.
conclusionshsCRP 1 month post-MI does not relate to acute cardiac injury or LV function at follow-up, but we confirm that peak CRP is an independent predictor of LV dysfunction at follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.